OxPL/apoB, lipoprotein(a) and OxLDL biomarkers and cardiovascular disease in chronic hemodialysis patients.J Nephrol. 2011 Sep-Oct; 24(5):581-8.JN
The aim of this study was to assess the correlation between oxidized phospholipids on apolipoprotein B-100 particles (OxPL/ApoB), lipoprotein(a) and low-density lipoprotein (LDL)-producing oxidized phospholipid (OxLDL) biomarkers and cardiovascular disease (CVD) in chronic hemodialysis (HD) patients.
In 52 HD patients, we measured OxPL/apoB by antibody E06, IgG/IgM autoantibody titers to copper-oxidized LDL (Cu-OxLDL) and malondialdehyde (MDA)-LDL, IgG/IgM apolipoprotein B-100-immune complexes (IC/apoB), C-reactive protein (CRP) and lipoprotein(a) (Lp(a)). In all patients, the presence of CVD was assessed.
OxPL/ApoB, IC IgG/IgM, MDA-LDL Ig G/IgM, Cu-OxLDL IgG/IgM and Lp(a) levels were similar in patients with and without CVD. At multiple logistic regression analysis, the association between age and CVD was independent (OR=1.078; 95% confidence interval, 1.005-1.157; p=0.03).
In HD patients, OxPL/apoB, lipoprotein(a) and OxLDL biomarkers are not associated with CVD.